Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on SKYEPHARMA PLC. We currently have 48 research reports from 4 professional analysts.
|09Jun16 10:54||RNS||Court sanction of Scheme of Arrangement|
|08Jun16 08:32||RNS||Holding(s) in Company|
|07Jun16 14:56||RNS||Technology License Agreement|
|20May16 15:36||GNW||Majedie Asset Management Ltd : Form 8.3 - SKYEPHARMA PLC|
|20May16 07:00||RNS||Recommended all share merger|
|19May16 14:37||GNW||Majedie Asset Management Ltd : Form 8.3 - SKYEPHARMA PLC|
|18May16 15:14||GNW||Majedie Asset Management Ltd : Form 8.3 - SKYEPHARMA PLC|
Frequency of research reports
Research reports on
Exclusive agreement with Lucideon
08 Jun 16
N+1 Singer acts as broker and adviser to Skyepharma. We have withdrawn our forecasts in line with rules of The Panel on Takeovers and Mergers during the offer period (Skyepharma and Vectura Group announced a recommended merger on 16th March 2016). This note reproduces the RNS released at 2:56pm on 7th June 2016.
AGM trading update
18 May 16
N+1 Singer acts as broker and adviser to Skyepharma. We have withdrawn our forecasts in line with rules of The Panel on Takeovers and Mergers during the offer period (Skyepharma and Vectura Group announced a recommended merger on 16th March 2016). This note reproduces the RNS released at 7am on the 18th May 2016. Skyepharma provided an update ahead of its Annual General Meeting.
2015 results; proposed merger with Vectura
23 Mar 16
Skyepharma reported 2015 results and a proposed merger with Vectura on 16th March. The enlarged group would have significant expertise across three inhalation delivery platforms (pMDI, DPI and nebulisers). The proposed terms of the deal offers Skyepharma shareholders 2.7977 Vectura shares per Skyepharma share, currently valuing Skyepharma at c.£470.8m. Skyepharma’s shareholders will own 41.75% of the enlarged group before any of the partial cash alternative (up to £70m) is paid. Skyepharma reported a 46% increase in 2015 EBIT to £31.5m.
Interim results lead to upgrades
27 Mar 17
Bioventix reported a strong set of interim results with revenues increasing by 32% (c.12-17% at constant exchange rates (CER)), driven largely by the continued roll-out of its customers’ Vitamin D assay products. This, in turn, led to a 41% increase in pre-tax profits and a 40% increase in adjusted EPS; which is reflective of the operational gearing of the business. We are upgrading our adjusted EPS to 78.7p (+5%) and, consequently, are raising our target price to 1750p. At this price level, the shares would trade on a 22.4x FY 2018 P/E and an EV/EBITDA of 17x. We await confirmation of Siemen’s high sensitivity troponin assay launch, expected in FY 2018.
27 Mar 17
Elecosoft* (ELCO): Steadily building profits (CORP) | Bioventix* (BVXP): Interim results lead to upgrades (CORP) | Hurricane Energy (HUR): Halifax discovery (BUY) | KBT Business Technology* (KBT): interims and contract win (CORP) | Independent Oil & Gas* (IOG): Licence updates (CORP)
28 Mar 17
ClearStar* (CLSU): Building a background for growth (CORP) | Sound Energy (SOU): TE-8 results (HOLD) | LiDCO* (LID): 2017 should be a transformative year (CORP) | Proteome Sciences* (PRM): FY 2016 in line. Moving towards breakeven (CORP) | Fulcrum (FCRM): Significant market potential, rising margins and a strong balance sheet (BUY) | Mortgage Advice Bureau (MAB1): Strong and growing intellectual property (BUY) | 7digital* (7DIG): Open offer result (CORP)
Small Cap Breakfast
28 Mar 17
Path Investments—Publication of prospectus from the Energy Investment Company. Raising £1.4m. Admission due on or around 30 March | Franchise Brands—Schedule 1 detailing £28m reverse takeover of Metro Rod. Admission expected 11 April | Alpha FX Group— Schedule 1 from the foreign exchange provider focused on managing exchange rate risk for UK corporates that trade internationally. Fundraise TBC. Admission expected 7 April. | K3 | Capital Group—Schedule 1 from the Group of business and company sales specialists across business transfer, business brokerage and corporate finance. Admission date and fundraise details TBC. | Integumen— Schedule 1 from the personal health company developing and commercialising technology and products for the human integumentary system. Raising £2.16m at 5p. Expected market cap £8.16m. Admission expected 5 April. Tufton | Oceanic Assets– Offer extended to 9 May to enable investors to complete further due diligence.
Sinclair Pharma - Aesthetically Positioned to Continue Double-Digit Growth
23 Mar 17
With an innovative and differentiated product portfolio of injectable devices addressing the fast-growing aesthetics market, Sinclair is best positioned to continue to achieve double-digit revenue growth in the medium term.
N+1 Singer - Morning Song 28-03-2017
28 Mar 17
A G Barr (BAG LN) Share buybacks the main news around FY17 finals | Churchill China (CHH LN) An excellent set of 2016 results and more upgrades | Ergomed (ERGO LN) FY results show strong Services growth; Phase III Zoptrex® data ahead | Instem (INS LN) Investment to accelerate growth trajectory | Severfield (SFR LN) Strong H2 drives upgrades; CEO temporarily steps down due to ill health | Summit Therapeutics (SUMM LN) Strengthening the data package: planned extension of PhaseOut DMD | T. Clarke (CTO LN) Strong conclusion to FY16, record order book